The company"s scientists had discovered a powerful adjuvant called Matrix-M, which comes from the inner bark of the Chilean soapbark tree, Quillaja saponaria. In a Phase III trial – usually the final stage of initial testing, involving large numbers of people – it not only yielded a stronger antibody response than existing influenza shots, but also provided cross-protection against multiple strains of flu.